Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the issuance of U.S. Patent No. 10,022,483 (“the ‘483 Patent”). The ‘483 Patent protects key features of the Aethlon Hemopurifier, a first-in-class therapeutic device, designed to treat viral infections. Previously, Aethlon received U.S. Patent Number 7,226,429, protecting the Company’s proprietary methods of treating viral infections. Together, this intellectual property further secures Aethlon’s position as a leader in pioneering therapeutic device strategies to address life-threatening virus outbreaks.
The Aethlon Hemopurifier is a first-in-class medical device designed for the single-use elimination of infectious viruses from the circulatory system of infected individuals. The Hemopurifier has been designated a “Breakthrough Device” by the United States Food and Drug Administration (FDA) related to the treatment of life-threatening viruses that are not addressed with approved therapies. Based on human and non-human clinical studies, the Hemopurifier is also a candidate to fulfill the broad-spectrum treatment countermeasure objectives set forth by the United States Department of Health and Human Services (HHS) to protect citizens against high threat pathogens that are not addressed with traditional drug and vaccine therapies.
